What Is Bismuth Tribromophenate Used For?

Bismuth tribromophenate is an antimicrobial compound used almost exclusively in wound care, where it serves as the active ingredient in petrolatum-impregnated gauze dressings applied to burns, surgical sites, and chronic wounds. Most people encounter it without knowing its name: it is the yellowish, slightly medicinal-smelling substance in Xeroform gauze, a staple of burn units and plastic surgery departments for decades. Its role in medicine is narrow but well established, and the ongoing research around it is less about discovering new uses than about figuring out when newer alternatives do the job better.

What Bismuth Tribromophenate Actually Is

Bismuth tribromophenate is a chemical compound that combines bismuth, a heavy metal with a long history in medicine, with tribromophenol, a brominated antiseptic. In its commercial wound-care form, the compound is mixed at a concentration of about 3% into petroleum jelly and spread onto fine mesh gauze.¹ The petroleum base keeps the dressing from sticking directly to raw tissue, while the bismuth tribromophenate provides a low-level antimicrobial effect at the wound surface. This combination has been in clinical use for decades in burn and plastic surgery settings, primarily as a covering for partial-thickness burns, skin graft donor sites, and other open wounds that need protection while they heal.

How It Fights Bacteria

Bismuth, like silver and other metals, interferes with bacterial survival at a cellular level. When researchers tested Xeroform gauze against plain gauze in a standard antimicrobial assay, the bismuth-impregnated dressing prevented bacterial growth in the area directly under it, while plain gauze did not inhibit growth at all.² The key distinction is that the effect was bacteriostatic rather than bactericidal. In plain terms, the dressing stopped bacteria from multiplying in the wound bed it covered, but it did not kill bacteria beyond the edges of the gauze. Think of it as a zone of suppression directly under the dressing rather than an antiseptic that radiates outward.

This is an important practical point. Bismuth tribromophenate dressings are not a replacement for systemic antibiotics when a wound is already infected. They are a preventive measure: by keeping bacterial colonies from establishing themselves on raw tissue, they buy the wound time to heal without the complication of infection. The antimicrobial action is modest compared to silver-based products or antibiotic creams, but it is real and has kept the dressing in clinical use even as flashier alternatives have come along.

The Primary Clinical Use: Burn Dressings and Skin Graft Donor Sites

If you have surgery that involves taking a split-thickness skin graft, the place on your body where the graft was harvested (the donor site) is essentially an open wound that needs to heal on its own. Covering that donor site is one of the most common jobs for bismuth tribromophenate gauze. Surgeons lay the petrolatum-impregnated mesh over the raw donor site, and the dressing stays in place while new skin grows underneath. The petroleum jelly prevents the gauze from bonding to the wound, making eventual removal less painful, while the bismuth compound discourages surface infection.

Partial-thickness burns, the kind where the top layers of skin are damaged but the deeper layers survive, are another core application. The dressing protects the burn surface, maintains a degree of moisture, and provides that low-level antimicrobial barrier. In many burn centers, bismuth tribromophenate gauze has been the default first-line dressing for these injuries simply because it is familiar, widely available, and inexpensive.¹

How It Compares to Silver-Based Dressings

Silver has been the dominant antimicrobial metal in wound care for years, and the comparison between silver-based products and bismuth tribromophenate gauze is a recurring theme in the surgical literature. A large retrospective study across two burn centers compared Xeroform dressings to a silver-impregnated foam dressing (Mepilex Ag) on skin graft donor sites and found a striking difference in infection rates: roughly 1% in the silver foam group versus about 11% in the bismuth-petrolatum gauze group.³ Patients whose donor sites were dressed with Xeroform had roughly ten times the odds of developing an infection compared to those with the silver dressing.

Pain scores and opioid use, on the other hand, did not differ between the two groups. So the silver foam was not more comfortable day-to-day; it just prevented infection far more effectively. The title of that study, “Bad Habits Die Hard,” is a blunt editorial statement: the authors argue that many surgeons stick with bismuth-petrolatum gauze out of familiarity rather than evidence. Whether that judgment is fair depends partly on cost, which we will get to, but the infection-rate gap is hard to ignore for high-stakes donor sites.

This does not mean bismuth tribromophenate gauze is ineffective. Its bacteriostatic activity is genuine, and in wounds with a low baseline infection risk, the difference between it and a silver product may be clinically irrelevant. The study above looked specifically at skin graft donor sites, which are large, open wounds in patients who often have other injuries. For a small, clean wound in an otherwise healthy person, the performance gap narrows.

Pediatric Burn Care

Children with scald burns, one of the most common pediatric burn injuries, represent a somewhat different clinical picture. A retrospective study comparing Xeroform gauze to silver sulfadiazine cream in children with mixed-depth scald injuries found that the two approaches led to similar overall skin grafting rates. About 15% of children treated with silver sulfadiazine cream needed a graft, compared to roughly 18% of those treated with Xeroform, a difference that was not statistically meaningful.⁴

Where the two approaches did differ was in the details. When grafting was necessary, children in the Xeroform group needed grafts that were on average about half the size of those in the silver sulfadiazine group. That suggests the bismuth-petrolatum dressing may have allowed more of the wound to heal on its own before grafting became necessary. However, the time from injury to grafting was significantly longer in the Xeroform group, averaging 24 days compared to about 10 days in the silver group. Whether that longer wait is acceptable depends on the clinical context: a smaller graft is better, but a longer healing trajectory means more wound care visits and more time at risk.

The takeaway for pediatric burns is that bismuth tribromophenate gauze is a viable option, not a clearly inferior one. It performs differently from silver-based products rather than worse across the board, and the choice between them often comes down to a surgeon’s assessment of the individual wound.

Chronic Wounds and Diabetic Foot Ulcers

Beyond acute burns and surgical sites, bismuth tribromophenate gauze shows up in the management of chronic wounds, particularly diabetic foot ulcers. In this setting, the dressing is typically used as a standard-of-care control rather than a cutting-edge treatment. One trial comparing a microbial cellulose dressing to Xeroform gauze in patients with type II diabetes found that ulcers treated with the cellulose material healed in an average of about 32 days, while those dressed with Xeroform took closer to 48 days.⁵

That difference is substantial, but it also tells you something about the role bismuth tribromophenate gauze occupies in wound care generally. It is the established baseline, the thing newer products are tested against. It works: the ulcers in the control group did heal. They just healed more slowly than with the newer material. For patients who lack access to advanced wound care products, or whose insurance does not cover them, bismuth tribromophenate gauze remains a functional and affordable option.

Reconstructive and Nasal Surgery

A less obvious but genuinely interesting application appears in facial reconstructive surgery. When surgeons place skin grafts inside the nostrils, keeping the graft in contact with the underlying tissue while still allowing the patient to breathe is a real engineering problem. A recently described device uses a nasal cannula for airflow, a surgical sponge for gentle pressure, and fine mesh gauze impregnated with 3% bismuth tribromophenate to promote healing and prevent infection around the graft.⁶ The bismuth-impregnated gauze is chosen here for the same properties that make it useful in burn care: it is conformable, non-adherent, and provides a mild antimicrobial environment without requiring frequent dressing changes in a difficult-to-access location.

This kind of niche surgical application is where bismuth tribromophenate gauze may have its most durable future. In large-area wound care, silver and other advanced dressings are gaining ground. But for small, awkward anatomical sites where you need a thin, conformable, non-adherent dressing that discourages infection, the traditional bismuth-petrolatum formulation is hard to beat on practicality.

Questions About Cell Compatibility

One concern that has emerged from laboratory research is how bismuth tribromophenate dressings interact with living cells at a microscopic level. A study that cultured human skin cells (keratinocytes) directly on various wound dressings found that cells placed on Xeroform gauze did not attach to the surface and did not survive through the first week of observation.⁷ Several other dressings in the study showed the same result, so this was not unique to the bismuth compound, but it does raise a question about whether the dressing material creates a surface that is actively inhospitable to the very cells you want to grow.

In practice, this lab finding has not translated into an obvious clinical problem. Wounds dressed with bismuth tribromophenate gauze do heal, as the clinical studies above confirm. The likely explanation is that in a real wound, new skin cells grow from the wound bed underneath the dressing rather than needing to colonize the dressing surface itself. The dressing sits on top, provides its barrier function, and eventually gets removed once healing is underway. Still, the finding is worth knowing about, especially as wound care evolves toward “bioactive” dressings that are designed to actively support cell migration. By that standard, bismuth tribromophenate gauze is passive at best.

Cost and Why It Still Gets Used

For all the evidence suggesting that silver and cellulose dressings outperform bismuth tribromophenate gauze in certain contexts, cost is the elephant in the room. Xeroform gauze is cheap. It has been manufactured for a long time, the raw materials are inexpensive, and it does not require a complex delivery system. Researchers who have experimented with making their own bismuth-petrolatum dressings by hand, mixing 3% bismuth tribromophenate powder into petroleum jelly and applying it to plain gauze, have confirmed that the antimicrobial performance of the homemade version matches the commercial product.² The explicit goal of that work was to identify a low-cost alternative for resource-limited settings.

A separate study tried layering a high-density polyethylene sheet over standard bismuth-petrolatum gauze to see if the added layer would improve donor-site healing or patient comfort. It found no clinically meaningful difference between the two-layer approach and bismuth-petrolatum gauze alone, leading the researchers to conclude that the simpler, single-layer dressing was the more cost-effective choice.⁸ This is a recurring pattern in the bismuth tribromophenate literature: adding complexity to the dressing does not reliably improve outcomes, and the basic formulation holds its own as a budget-friendly workhorse.

In well-funded hospitals, silver-based dressings and advanced wound-care products are increasingly the standard for high-risk wounds. But in community hospitals, outpatient clinics, field hospitals, and healthcare systems in lower-income countries, bismuth tribromophenate gauze remains a practical choice. It is not the best-performing option available in 2024, but it is one of the most accessible, and a dressing that works and is available beats a superior dressing that is not.

Why You Might Encounter It Outside a Hospital

Bismuth tribromophenate gauze is not just a hospital product. It is available through medical supply retailers and sometimes shows up in first-aid kits marketed to outdoors enthusiasts, preppers, and people who keep extensive home medical supplies. In veterinary medicine, the same gauze is used on animals for wound management, particularly on horses and livestock where large open wounds are common and frequent dressing changes are impractical. The non-adherent, low-maintenance nature of the dressing makes it well suited to settings where a wound needs to be covered and then largely left alone for a stretch of time.

If you buy Xeroform gauze over the counter and apply it to a minor wound at home, you are using the same product that burn surgeons reach for in the operating room. The active ingredient is identical; the difference is in the severity of the wound and the level of follow-up care. For a clean, superficial wound that you would otherwise cover with a plain adhesive bandage, the antimicrobial bump from bismuth tribromophenate is a modest but real upgrade. For anything deeper, more contaminated, or slower to heal, professional wound assessment is still the right call, regardless of what dressing you use in the interim.